Literature DB >> 20372873

Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study.

A M Arafat1, M Möhlig, M O Weickert, C Schöfl, J Spranger, A F H Pfeiffer.   

Abstract

AIMS/HYPOTHESIS: Growth hormone-deficient patients show deterioration of insulin sensitivity and beta cell function. High-dose growth hormone treatment often induces further impairment of insulin sensitivity, leading to an increase in insulin and glucose levels or even, in cases of preexisting beta cell defect, to overt diabetes. However, low-dose treatment may improve insulin sensitivity, although data in humans with detailed metabolic phenotyping are as yet not available. We postulated that long-term low-dose growth hormone replacement, restoring IGF-1 to the low-normal range, might beneficially affect glucose metabolism.
METHODS: We studied prospectively the metabolic responses to 24 and 48 weeks of growth hormone treatment in a small group of six adults with severe growth hormone deficiency (four men, two women; age 40-59 years; BMI 30.2 +/- 1 kg/m(2); mean growth hormone dose 0.3 +/- 0.04 mg/day). All participants underwent an oral glucose tolerance test, euglycaemic-hyperinsulinaemic clamp and hyperglycaemic-hyperinsulinaemic clamp plus i.v. L: -arginine on three occasions. Insulin sensitivity was measured by calculating the M value during the steady state of the euglycaemic-hyperinsulinaemic clamp. Insulin secretion and clearance were estimated from AUC(C-peptide), AUC(insulin) and their ratio at each phase of the hyperglycaemic-hyperinsulinaemic clamp.
RESULTS: Growth hormone significantly improved insulin sensitivity (M value 13.8 +/- 2.6 [baseline] vs 19.6 +/- 2.6 [24 weeks] and 23.7 +/- 1.9 [48 weeks] micromol kg(-1) min(-1); p < 0.01). Although the insulin response to glucose and arginine decreased slightly, the disposition index, integrating insulin sensitivity and secretion, significantly increased (p < 0.01), indicating an improvement in whole-body glucose metabolism. Insulin clearance was not affected during treatment (p > 0.05). CONCLUSIONS/
INTERPRETATION: Our data indicate that long-term low-dose growth hormone treatment may improve insulin sensitivity and whole-body glucose metabolism in adults with severe growth hormone-deficiency.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372873     DOI: 10.1007/s00125-010-1738-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  50 in total

Review 1.  Growth hormone replacement therapy for adults: into the new millennium.

Authors:  Helen Simpson; Richard Savine; Peter Sönksen; Bengt-Ake Bengtsson; Lena Carlsson; Jens Sandahl Christiansen; David Clemmons; Pinchus Cohen; Raymond Hintz; Ken Ho; Primus Mullis; Iain Robinson; Christian Strasburger; Toshiaka Tanaka; Michael Thorner
Journal:  Growth Horm IGF Res       Date:  2002-02       Impact factor: 2.372

2.  Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men.

Authors:  Lucia I Arwert; Jan C Roos; Paul Lips; Jos W R Twisk; Radu A Manoliu; Madeleine L Drent
Journal:  Clin Endocrinol (Oxf)       Date:  2005-09       Impact factor: 3.478

Review 3.  Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.

Authors:  Kevin C J Yuen; David B Dunger
Journal:  Growth Horm IGF Res       Date:  2006-04-18       Impact factor: 2.372

Review 4.  Growth hormone and metabolism.

Authors:  M Press
Journal:  Diabetes Metab Rev       Date:  1988-06

5.  One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults.

Authors:  Cesar L Boguszewski; Ludimyla H F Meister; Daniele C T Zaninelli; Rosana B Radominski
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

6.  A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance.

Authors:  B Bülow; E M Erfurth
Journal:  Clin Endocrinol (Oxf)       Date:  1999-01       Impact factor: 3.478

7.  Activation of phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition of pancreatic beta-cell death.

Authors:  Wenli Liu; Catherine Chin-Chance; Eun-Jig Lee; William L Lowe
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

8.  Quantitative study of insulin secretion and clearance in normal and obese subjects.

Authors:  K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

9.  Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study.

Authors:  U Plöckinger; T Reuter
Journal:  Eur J Endocrinol       Date:  2008-04       Impact factor: 6.664

10.  The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance.

Authors:  Vaclav Hana; Josef V Silha; Vlasta Justova; Zdena Lacinova; Jan J Stepan; Liam J Murphy
Journal:  Clin Endocrinol (Oxf)       Date:  2004-04       Impact factor: 3.478

View more
  13 in total

1.  Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniopharyngioma and non-functioning pituitary adenoma.

Authors:  E Profka; C Giavoli; S Bergamaschi; E Ferrante; E Malchiodi; E Sala; E Verrua; G Rodari; M Filopanti; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2014-10-21       Impact factor: 4.256

2.  Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment.

Authors:  A Ciresi; M C Amato; C Giordano
Journal:  J Endocrinol Invest       Date:  2014-10-02       Impact factor: 4.256

3.  5'AMP-activated protein kinase activity is increased in adipose tissue of northern elephant seal pups during prolonged fasting-induced insulin resistance.

Authors:  Jose A Viscarra; Cory D Champagne; Daniel E Crocker; Rudy M Ortiz
Journal:  J Endocrinol       Date:  2011-03-23       Impact factor: 4.286

4.  Improved adipose tissue metabolism after 5-year growth hormone replacement therapy in growth hormone deficient adults: The role of zinc-α2-glycoprotein.

Authors:  Miroslav Balaž; Barbara Ukropcova; Timea Kurdiova; Miroslav Vlcek; Martina Surova; Patrik Krumpolec; Peter Vanuga; Daniela Gašperíková; Iwar Klimeš; Juraj Payer; Christian Wolfrum; Jozef Ukropec
Journal:  Adipocyte       Date:  2014-12-17       Impact factor: 4.534

5.  Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA).

Authors:  A Ciresi; F Cicciò; M C Amato; C Giordano
Journal:  J Endocrinol Invest       Date:  2015-05-27       Impact factor: 4.256

6.  The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.

Authors:  Alessandro Ciresi; Stefano Radellini; Valentina Guarnotta; Carla Giordano
Journal:  Endocrine       Date:  2016-08-13       Impact factor: 3.633

7.  Systematic evaluation of validated type 2 diabetes and glycaemic trait loci for association with insulin clearance.

Authors:  M O Goodarzi; X Guo; J Cui; M R Jones; T Haritunians; A H Xiang; Y-D I Chen; K D Taylor; T A Buchanan; W A Hsueh; L J Raffel; J I Rotter
Journal:  Diabetologia       Date:  2013-03-14       Impact factor: 10.122

8.  Short-term, low-dose GH therapy improves insulin sensitivity without modifying cortisol metabolism and ectopic fat accumulation in adults with GH deficiency.

Authors:  Kevin C J Yuen; Charles T Roberts; Jan Frystyk; William D Rooney; James R Pollaro; Bethany J Klopfenstein; Jonathan Q Purnell
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

9.  Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia.

Authors:  N J M van Beveren; E Schwarz; R Noll; P C Guest; C Meijer; L de Haan; S Bahn
Journal:  Transl Psychiatry       Date:  2014-08-26       Impact factor: 6.222

10.  Effects of growth hormone (GH) therapy withdrawal on glucose metabolism in not confirmed GH deficient adolescents at final height.

Authors:  Flavia Prodam; Silvia Savastio; Giulia Genoni; Deepak Babu; Mara Giordano; Roberta Ricotti; Gianluca Aimaretti; Gianni Bona; Simonetta Bellone
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.